VENTURE (12+ years), TRAVERSE OLE (12+ years)

86% of patients reduced or eliminated their OCS dose at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) (ITT population, VENTURE).¹³

A 70% significant reduction in OCS dose (median 100%) from baseline was observed at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint).¹

In addition, 79% of patients from VENTURE eliminated their OCS dose at Week 96 in the TRAVERSE OLE study (secondary endpoint).⁹

• A gradual increase in the number of patients eliminating their OCS dose was observed from 53.3% at Week 0 (n=48) to 59.6% at Week 48 (n=34) to 78.9% at Week 96 (n=15) in the DUPIXENT/DUPIXENT group.^9,d

Results from TRAVERSE are descriptive. There are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.